IL2 and neoplasm: PD1 combined with PD-L1 can inhibit the proliferation and activation of CD4- and CD8-positive T cells, downregulate the secretions of interleukin-2 and interferon-γ, and finally inhibit the immune function of T cells, thereby forming an immunosuppressive tumor microenvironment in which tumor cells escape the host’s immune system.